Affiliate disclosure: Some links in this article are affiliate links. We may earn a commission at no additional cost to you.

Medical disclaimer: This article reviews published research on NAD+ biology and aging. It is not medical advice, diagnosis, or treatment. Not medical advice. Consult a qualified healthcare professional before changing your supplement regimen, diet, or any health-related practice, particularly if you have existing medical conditions or take prescription medications.

Every major molecular pathway covered in the longevity research cluster on this site — sirtuins, mTOR-linked autophagy, FOXO3 stress response, epigenetic DNA repair, cellular senescence — eventually connects back to a single small molecule: nicotinamide adenine dinucleotide, or NAD+.

That convergence is not a coincidence of framing. NAD+ is the co-substrate consumed in each SIRT1 and SIRT6 catalytic cycle. It is required for PARP-mediated DNA strand break repair. It is the molecule whose intracellular concentration tracks cellular energy state and ultimately limits how actively the longevity-relevant enzyme families can function. In that sense, NAD+ is less one pathway among many and more the common substrate condition on which several of the others depend.

And it declines measurably — sometimes steeply — as organisms age.

TL;DR

• NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every mammalian cell, functioning as a co-substrate for sirtuin deacylases, PARP DNA repair enzymes, and cellular energy transfer through the NAD+/NADH redox cycle in the mitochondria
• Cross-sectional tissue data consistently shows lower NAD+ concentrations in aged tissue than in young tissue; Verdin’s 2015 Science review synthesized available evidence and cited declines of 50-80% in specific tissues — notably skeletal muscle and brain — between young and old samples
• Three mechanisms appear to drive this decline concurrently: reduced NAMPT activity (the rate-limiting enzyme in the main NAD+ regeneration route), elevated CD38 activity (a NAD+-consuming enzyme that rises with age and inflammatory state), and increased PARP activation competing with sirtuins for the available NAD+ pool
• Shin-ichiro Imai (今村真一), now professor at Washington University School of Medicine in St. Louis following earlier longevity research in Japan, has been among the most prominent investigators of NMN as an NAD+ precursor strategy — his lab produced key mouse aging studies and co-led the Yoshino et al. 2021 Science human RCT showing skeletal muscle insulin sensitivity improvement at 250 mg/day NMN
• NMN and NR (nicotinamide riboside) are two NAD+ precursors that reach the NAD+ pool via different enzymatic routes; niacin (nicotinic acid, NA) and nicotinamide (NAM) complete the main precursor family with distinct mechanisms and regulatory profiles
• Calibration: NAD+ decline with aging is well-documented in tissue cross-sections; whether raising NAD+ through supplementation in humans produces meaningful clinical outcomes in longevity-relevant endpoints has not been established beyond early-stage biomarker and metabolic data; the Imai lab itself consistently describes NMN research as a work in progress

What NAD+ does — and why the concentration matters

NAD+ and its reduced form NADH are the central electron carriers of cellular energy metabolism. In glycolysis and the tricarboxylic acid (TCA) cycle, enzymatic reactions transfer electrons to NAD+, reducing it to NADH; the electron transport chain then oxidizes NADH back to NAD+, driving ATP synthesis. This cycling is fundamental to mitochondrial function — without adequate NAD+ to accept electrons, oxidative phosphorylation stalls.

NAD+ also serves as a co-substrate in a functionally separate set of reactions that consume it non-cyclically. Every sirtuin deacylation cycle — SIRT1 removing an acetyl group from a transcription factor, SIRT3 activating a TCA cycle enzyme, SIRT6 mediating histone deacetylation at a DNA repair site — consumes one NAD+ molecule and releases nicotinamide (NAM) as a byproduct. PARP enzymes, which respond to DNA strand breaks by attaching poly-ADP-ribose chains to proteins near the damage, consume NAD+ in substantial quantities under conditions of significant DNA damage. CD38, a bifunctional ectoenzyme that produces the calcium signaling molecule cADPR and directly degrades NAD+ to NAM and ADP-ribose, operates as an additional consumer.

The consequence is that cellular NAD+ availability is not static. It is continuously depleted by enzymatic demand across these consumer families and continuously regenerated through two main routes. The salvage pathway — the dominant route in most mammalian tissues — converts NAM back to NMN via NAMPT (nicotinamide phosphoribosyltransferase), then converts NMN to NAD+ via NMNAT enzymes. NAMPT is the rate-limiting step in this pathway. The Preiss-Handler pathway converts nicotinic acid (NA, dietary niacin) through a three-step enzymatic route to NAD+. When the balance between consumption and regeneration shifts — through increased consumer activity, reduced salvage capacity, or both — NAD+ concentration falls.

How steeply NAD+ falls with age: Verdin’s 2015 Science review

The 2015 review paper by Eric Verdin — then director of the Gladstone Institute of Virology and Immunology at UCSF, subsequently CEO of the Buck Institute for Research on Aging — synthesized the available cross-sectional evidence on tissue NAD+ levels across the age spectrum in both rodents and humans. The figure that has since been widely cited: NAD+ concentrations in aged tissue can be 50-80% lower than in young tissue in specific tissue contexts, with skeletal muscle and brain among the most consistently documented.

Several calibration points attach to this number. The 50-80% range spans multiple tissues, multiple species, and studies collected under different methods of NAD+ quantification — mass spectrometry, enzymatic assay, and others with varying sensitivity profiles. The decline is real and consistently replicated in the cross-sectional literature; the exact magnitude in any specific human tissue at a specific age is harder to pin down than the headline figure implies. Available human tissue data draws primarily from peripheral blood mononuclear cells and skeletal muscle biopsies — brain tissue NAD+ data in living humans is limited to indirect inference from blood measurements or from post-mortem samples with their own confounders.

Causality is also a live research question. Whether NAD+ decline drives cellular aging — through reduced sirtuin activity, impaired PARP-mediated DNA repair, and diminished mitochondrial function — or whether it is a consequence of accumulating other aging-associated damage is not established at the clinical evidence level. Preclinical work in rodents strongly supports the causal direction: NAMPT overexpression in mice (which maintains higher NAD+ levels with aging) is associated with preserved metabolic function. Mouse models of deliberate NAD+ depletion show accelerated aging-like phenotypes. The translation of these findings to human biology remains a research question rather than a settled fact.

Why NAD+ declines: three concurrent mechanisms

NAMPT activity decline. NAMPT is the rate-limiting enzyme in the salvage pathway — the primary NAD+ regeneration route in most mammalian tissues. Rodent aging studies have found lower NAMPT protein levels and activity in aged tissue compared to young tissue, particularly in skeletal muscle and adipose tissue. NAMPT expression is also rhythmically regulated by the circadian clock, with SIRT1 itself participating in a feedback loop that sustains NAMPT expression — this connects sleep and circadian rhythm disruption to NAD+ metabolism through a documented molecular mechanism. Whether NAMPT activity declines in human tissues proportionally to what rodent data suggests has not been fully characterized with human biopsy data at scale.

CD38 accumulation. CD38 is a NAD+-consuming ectoenzyme whose expression increases with age and with chronic inflammatory state in multiple tissue datasets — and is notably high in immune cells infiltrating aged tissues. This creates a feedback dynamic: age-associated sterile inflammation (inflammaging) drives elevated CD38, which depletes NAD+, which reduces sirtuin-mediated regulation of inflammatory gene programs, which sustains the inflammatory state. The CD38 / NAD+ / inflammaging axis is one of the more mechanistically concrete proposed links by which chronic low-grade inflammation might accelerate molecular aging independently of acute disease. CD38 inhibition by the dietary flavonoid apigenin has shown NAD+-sparing effects in cell culture and animal models; this remains preclinical work.

PARP hyperactivation under cumulative DNA damage. As DNA damage accumulates with aging, PARP activation frequency increases. PARP enzymes are major NAD+ consumers under active damage conditions. If PARP activation rate rises with aging-associated DNA damage, the NAD+ pool faces sustained elevated depletion from this direction concurrent with declining salvage pathway regeneration. SIRT6, the DNA repair sirtuin that mediates histone deacetylation at H3K9 and H3K56 sites and facilitates double-strand break repair, requires adequate NAD+ to function — lower NAD+ means reduced SIRT6 activity means less efficient DNA repair means more unrepaired damage means more PARP activation: a positive feedback dynamic between NAD+ depletion and DNA repair efficiency that several aging researchers have proposed as a driver of accelerating tissue decline with age.

Shin-ichiro Imai and the NMN research lineage

Shin-ichiro Imai (今村真一) — professor of developmental biology and medicine at Washington University School of Medicine in St. Louis — is among the investigators most closely associated with NMN’s transition from a laboratory compound to a clinical research focus.

Imai’s lab conducted key early rodent NMN studies, including work showing that NMN administration to aged mice was associated with maintained mitochondrial function in skeletal muscle, enhanced energy metabolism, and extended physical activity capacity — published across papers in Cell Metabolism and related journals through the 2013-2016 period. These animal studies established NMN’s oral bioavailability and its capacity to raise tissue NAD+ in aged rodents, providing the biological plausibility basis for moving to human trials.

A notable mechanistic finding from the Imai lab was the characterization of Slc12a8 as a putative intestinal NMN transporter in mice — suggesting that NMN might be absorbed intact in the intestinal epithelium rather than requiring prior dephosphorylation to NR. Whether an equivalent transporter mediates intact NMN absorption in humans has not been confirmed in human tissue data, though bioavailability studies have established that oral NMN raises blood NAD+ in humans regardless of the precise absorption mechanism.

Imai’s public research communications have been notably measured. His descriptions of NMN as potentially relevant to human aging consistently stop well short of longevity claims — the consistent framing from his group is that what mouse studies show is promising enough to warrant rigorous human trials, that those trials are ongoing, and that conclusions about human aging effects require evidence that has not yet been generated. This epistemic conservatism from a researcher who has spent decades on NAD+ biology is worth noting when evaluating the more expansive claims that appear in supplement marketing.

The precursor family: four routes to the NAD+ pool

NMN and NR have accumulated the most human trial data, but they are two members of a larger precursor family, each with different enzymatic routes and regulatory profiles:

Nicotinic acid (NA / niacin) is the original B3 vitamin form with the most established pharmacological history. At 1000-2000 mg/day, niacin has been used for decades as a lipid-modifying agent raising HDL and lowering triglycerides. Its route to NAD+ runs through the Preiss-Handler pathway: NA → nicotinic acid mononucleotide (NAMN) → nicotinic acid adenine dinucleotide (NAAD) → NAD+. At pharmacological doses, NA triggers a flushing reaction mediated by GPR109A receptor activation — a skin capillary prostaglandin response that limits tolerability. At lower dietary doses, it is simply dietary B3.

Nicotinamide (NAM) is the amide form of B3 that enters the salvage pathway directly: NAM → NMN via NAMPT. NAM is also the byproduct of both sirtuin and PARP reactions — what remains after NAD+ is consumed in each catalytic cycle. This creates a regulatory dynamic: NAM at elevated intracellular concentrations acts as a feedback inhibitor of both sirtuins and PARP, creating a ceiling on how high NAM-derived NAD+ can accumulate before the consumers themselves are suppressed.

NR (nicotinamide riboside) is phosphorylated by NR kinases (NRK1/2) to produce NMN inside cells, then converted to NAD+ by NMNAT enzymes. NR is backed by ChromaDex (the manufacturer of Tru Niagen), which has conducted the most extensive published human trial program for a single NR product. NR has slightly more total human trials than NMN and holds FDA GRAS status as a dietary supplement in the US. Whether NR and NMN reach target tissues equivalently, or whether one has pharmacokinetic advantages in specific tissue types, has not been resolved by current head-to-head human data.

NMN (nicotinamide mononucleotide) is converted directly to NAD+ by NMNAT enzymes. The Imai lab’s Slc12a8 transporter finding suggests that NMN may be absorbed intact at the intestinal level in mice, bypassing the NR intermediate step. In humans, oral NMN raises blood NAD+ in a dose-dependent fashion across multiple published trials. US regulatory status has additional complexity: in late 2022, the FDA announced NMN could not be marketed as a dietary supplement because of prior IND (Investigational New Drug) status, creating ongoing regulatory ambiguity in the US market — a practical distinction from NR, which carries a clean NDI (New Dietary Ingredient) acceptance.

What the Yoshino 2021 trial established — and what it did not

The Yoshino et al. 2021 Science paper is the most widely cited human NMN RCT, and its finding merits both full credit and precise framing.

25 postmenopausal women with prediabetes were randomized to 250 mg/day NMN or placebo for 10 weeks. The NMN group showed statistically significant improvement in skeletal muscle insulin sensitivity, measured by hyperinsulinemic-euglycemic clamp — the rigorous direct method — and gene expression changes in muscle consistent with improved insulin signaling, relative to placebo (PubMed 34108262). The trial was a Washington University / Keio University collaboration, and publication in Science reflects its methodological quality.

What this trial established: that 250 mg/day NMN for 10 weeks, in postmenopausal women with prediabetes, is associated with a measurable change in skeletal muscle insulin sensitivity and muscle gene expression under controlled conditions.

What it did not establish: that NMN improves insulin sensitivity in healthy adults, in men, in people with normal baseline insulin sensitivity, over longer periods, at different doses, or that insulin sensitivity improvement under clamp conditions translates to clinically meaningful downstream outcomes. No human trial has established that NMN supplementation affects longevity-relevant endpoints beyond this metabolic measure in this population.

The Igarashi et al. 2022 Keio University study added modest physical function signals (walking speed, grip strength) in older adults at 250 mg/day NMN over 12 weeks. Liao et al. 2023 established dose-response for blood NAD+ elevation across 300-900 mg/day, finding that the increment from 600 to 900 mg/day was substantially smaller than from 300 to 600 mg/day — suggesting NAD+-raising capacity plateaus above roughly 500-600 mg/day. The full trial-by-trial detail is in the NMN Supplements and Japanese Research article.

NAD+ as the shared substrate: connections across the research cluster

NAD+ is not simply one additional pathway — it is the shared substrate condition on which several of the better-characterized molecular aging pathways depend. A few specific connections are worth making explicit:

Sirtuins: SIRT1, SIRT2, SIRT3, and SIRT6 each consume one NAD+ molecule per catalytic cycle. Lower cellular NAD+ directly limits sirtuin activity regardless of enzyme expression levels; NAD+ repletion strategies have their proposed benefit for sirtuin function through this dependency. The sirtuin-NAD+ relationship, including the CALERIE Phase 2 caloric restriction trial data, is covered in the sirtuins and caloric restriction article.

Epigenetic clock and SIRT6: SIRT6 mediates histone deacetylation at H3K9 and H3K56 sites and appears to suppress epigenetic drift at repetitive genomic elements in model organism research. The CpG methylation patterns measured by Horvath-type clocks partly reflect the fidelity of this SIRT6-dependent maintenance. NAD+ availability as a modulator of SIRT6 activity is one proposed mechanistic link between NAD+ status and epigenetic aging rate — discussed in the epigenetic clock article.

Autophagy: SIRT1, at adequate NAD+ levels, deacetylates autophagy initiation proteins including ATG5, ATG7, and ATG8, supporting autophagic flux. The connection between NAD+ availability and autophagy induction runs through SIRT1 — mechanistically specific but indirect. The Nobel Prize-recognized autophagy biology is covered in the Ohsumi autophagy article.

FOXO3: SIRT1 deacetylates FOXO3, affecting its nuclear localization and transcriptional program — including stress response genes and autophagy regulators. The longevity-associated FOXO3 genetic variants characterized in the Willcox PNAS Japanese-American centenarian cohort function within a signaling context where NAD+/SIRT1 availability is a concurrent input. The FOXO3 genetics are covered in the FOXO3 article.

Senolytics and CD38: CD38 is expressed at elevated levels in senescent cells and in immune cells infiltrating senescent tissue. The NAD+ depletion effect of CD38 is therefore linked to senescent cell accumulation — clearing senescent cells (the target of senolytics) would in principle reduce CD38-mediated NAD+ drain. The senescent cell mechanisms are covered in the senolytics article.

mTOR and the caloric restriction cascade: AMPK, which activates during caloric restriction and mTOR suppression, is an upstream inducer of NAMPT expression in some cell types. SIRT1 participates in positive feedback on NAMPT transcription. The proposed sequence — mTOR suppression → AMPK activation → elevated NAMPT → elevated NAD+ → enhanced SIRT1 — represents one route by which caloric restriction benefits may flow through NAD+ metabolism, covered in the mTOR and caloric restriction article.

What the evidence does not establish

Several claims that circulate in popular NAD+ coverage are not supported by the current research base.

That NAD+ supplementation extends human lifespan. No human trial has measured lifespan as an endpoint. All NMN and NR trial endpoints to date are biomarker-level — blood NAD+, insulin sensitivity, walking speed, self-reported fatigue — at windows of 10-16 weeks in relatively small samples. These are early-stage findings, not longevity outcome evidence.

That NAD+ decline causes aging rather than accompanying it. Preclinical evidence for a causal role is suggestive — NAMPT overexpression preserving metabolic function, NAD+ depletion models accelerating aging phenotypes in rodents — but causality in humans at the tissue level has not been established from available data. Correlation in cross-sectional human tissue samples is what the evidence shows.

That supplementing NAD+ precursors replicates caloric restriction. Caloric restriction affects mTOR, AMPK, insulin signaling, and NAD+ simultaneously through an integrated metabolic shift. Supplementing one input to the system does not replicate that integrated state; the two interventions may converge on NAD+ effects through different starting conditions and different kinetics.

That one precursor is clearly superior to the other. Direct head-to-head comparison of NMN versus NR in tissue NAD+ outcomes has not been completed in humans at adequate sample sizes. Current evidence supports that both raise blood NAD+; equivalence or superiority in specific tissues or clinical outcomes remains an open question the current trial generation has not answered.

Reading further and supplement context

For readers tracking the research directly: Verdin’s 2015 Science review on NAD+ and aging is the primary synthesis document for the decline evidence. The Yoshino et al. 2021 Science paper (PubMed 34108262) is the primary human RCT for NMN’s metabolic effects. The Imai lab’s publications page at Washington University carries the full research lineage from mouse studies through human trials. David Sinclair’s Lifespan covers the NAD+ and sirtuin narrative for a general audience — available on Amazon.

On the supplement side: Tru Niagen (ChromaDex’s NR 300mg formulation, the most extensively published NR product in human trials) is available on Amazon. For NMN, Renue by Science (sublingual delivery format with published third-party testing data) is available on Amazon, and ProHealth Longevity NMN Pro (the high-dose formulation with quality documentation) is available on Amazon.

The Liao et al. 2023 dose-response data suggests blood NAD+-raising effect largely plateaus above roughly 500-600 mg/day NMN, which is worth noting when evaluating higher-dose products on a cost-per-NAD+-increment basis. The trial-by-trial detail on dosing and the Yoshino 2021 population specifics are in the NMN supplement article.

Potential interactions with diabetes medications have been flagged in the NMN research context given the insulin sensitivity findings. NR likely shares metabolic effects in this area. For either precursor, a clinician conversation before beginning is appropriate — and the conversation is most useful when grounded in what the evidence actually shows: that blood NAD+ rises with supplementation, that skeletal muscle insulin sensitivity improvement was observed in postmenopausal women with prediabetes at 250 mg/day NMN over 10 weeks, and that longevity outcome evidence in humans does not yet exist. That framing — which Imai’s own research communications apply consistently — is the calibration floor for evaluating claims in this space.

---

Research cluster: Sirtuins, NAD+, and Caloric Restriction | NMN Supplements and Japanese Research: What the RCTs Show | Epigenetic Clock and Japanese Longevity | FOXO3 and Okinawan Centenarian Genetics | mTOR, Caloric Restriction, and Aging | Cellular Senescence and Senolytics | Ohsumi’s Nobel and the Autophagy Research